Develops novel treatments for rare, chronic, and serious infectious diseases, focusing on improving patient outcomes.
AN2 Therapeutics, Inc. is a dynamic clinical-stage biopharmaceutical company that specializes in the development of groundbreaking treatments tailored specifically for rare, chronic, and serious infectious diseases. With a mission to revolutionize healthcare solutions, AN2 Therapeutics focuses on delivering innovative therapies that address critical unmet medical needs in the field of infectious diseases.
The cornerstone of AN2 Therapeutics' pipeline is epetraborole, a promising once-daily oral treatment aimed at patients battling chronic non-tuberculous mycobacterial lung disease. This condition represents a significant area of unmet medical need, and epetraborole's development signifies a potential breakthrough in providing effective and accessible treatment options for affected individuals.
Founded in 2017 and headquartered in Menlo Park, California, AN2 Therapeutics, Inc. embodies a commitment to scientific excellence and patient-centric innovation. By harnessing cutting-edge research and development capabilities, the company strives to transform the landscape of infectious disease management, offering hope and improved quality of life to patients worldwide.